carbonyloxy-camptothecin—is an in-hibitor of DNA topoisomerase I and is clinically effective against several can-cers. A major toxic effect of CPT-11 is severe diarrhea; however, the exact mechanism by which the drug induces diarrhea has not been established. Cisplatin (CDDP; CK-diamminedi-chloroplatinum) and CPT-11 exhibit synergistic antitumor activity and have been used in combination-chemother-apy regimens. Single-agent chemo-therapy with conventional doses of CDDP does not cause clinically rele-vant diarrhea. Purpose: To elucidat
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Chemotherapy-induced diarrhoea is a major oncological problem, caused by the cytotoxic effects of ca...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibite...
Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replicatio...
rinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited...
Introduction Irinotecan (CPT-11) is an inhibitor of DNA topoisomerase I and is clinically effective ...
diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced col...
Irinotecan (CPT-11) is a chemotherapeutic agent that selectively inhibits the DNA enzyme topoiso-mer...
This study was designed to evaluate irinotecan (CPT-11) disposition and pharmacodynamics in the pres...
While irinotecan (CPT-11) has a potent anti-cancer effect, it also causes serious diarrhea as an adv...
textabstractThis study was designed to evaluate irinotecan (CPT-11) disposition and pharma...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Irinotecan (CPT-11) is a chemotherapeutic drug used to treat tumors by acting on malignant cells thr...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Chemotherapy-induced diarrhoea is a major oncological problem, caused by the cytotoxic effects of ca...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibite...
Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replicatio...
rinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited...
Introduction Irinotecan (CPT-11) is an inhibitor of DNA topoisomerase I and is clinically effective ...
diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced col...
Irinotecan (CPT-11) is a chemotherapeutic agent that selectively inhibits the DNA enzyme topoiso-mer...
This study was designed to evaluate irinotecan (CPT-11) disposition and pharmacodynamics in the pres...
While irinotecan (CPT-11) has a potent anti-cancer effect, it also causes serious diarrhea as an adv...
textabstractThis study was designed to evaluate irinotecan (CPT-11) disposition and pharma...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Irinotecan (CPT-11) is a chemotherapeutic drug used to treat tumors by acting on malignant cells thr...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...
Chemotherapy-induced diarrhoea is a major oncological problem, caused by the cytotoxic effects of ca...
Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-p...